NBSE NeuBase Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NBSE

Price (delayed)

$0.41

Market cap

$1.53M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.7

Enterprise value

-$5.71M

NeuBase Therapeutics Inc. is accelerating the genetic revolution using a new class of synthetic medicines which have been shown to be able to increase, decrease and change gene function, as ...

Highlights
The company's EPS has surged by 63% YoY and by 35% QoQ
The net income has soared by 59% YoY and by 30% QoQ
NBSE's quick ratio has dropped by 51% year-on-year but it is up by 12% since the previous quarter
The equity has shrunk by 61% YoY and by 19% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.neubasetherapeutics.com
Peers: NWBO

Key stats

What are the main financial stats of NBSE
Market
Shares outstanding
3.73M
Market cap
$1.53M
Enterprise value
-$5.71M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.11
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$13.72M
EBITDA
-$12.55M
Free cash flow
-$14.84M
Per share
EPS
-$7.7
Free cash flow per share
-$5.38
Book value per share
$3.87
Revenue per share
$0
TBVPS
$6.75
Balance sheet
Total assets
$18.62M
Total liabilities
$9.48M
Debt
$5.34M
Equity
$9.14M
Working capital
$8.7M
Liquidity
Debt to equity
0.58
Current ratio
2.87
Quick ratio
2.7
Net debt/EBITDA
0.58
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-62.4%
Return on equity
-103.5%
Return on invested capital
-149.2%
Return on capital employed
-98.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBSE stock price

How has the NeuBase Therapeutics stock price performed over time
Intraday
-6.82%
1 week
-6.82%
1 month
-3.76%
1 year
-99.27%
YTD
-44.6%
QTD
-8.87%

Financial performance

How have NeuBase Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.27M
Net income
-$13.73M
Gross margin
N/A
Net margin
N/A
The net income has soared by 59% YoY and by 30% QoQ
NBSE's operating income has surged by 54% year-on-year and by 24% since the previous quarter

Growth

What is NeuBase Therapeutics's growth rate over time

Valuation

What is NeuBase Therapeutics stock price valuation
P/E
N/A
P/B
0.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 63% YoY and by 35% QoQ
The stock's P/B is 98% below its 5-year quarterly average of 5.2 and 63% below its last 4 quarters average of 0.3
The equity has shrunk by 61% YoY and by 19% QoQ

Efficiency

How efficient is NeuBase Therapeutics business performance
The return on invested capital is up by 49% year-on-year and by 21% since the previous quarter
The ROA has grown by 19% from the previous quarter and by 18% YoY
NeuBase Therapeutics's ROE has increased by 11% from the previous quarter but it has decreased by 6% YoY

Dividends

What is NBSE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBSE.

Financial health

How did NeuBase Therapeutics financials performed over time
The company's total assets is 96% higher than its total liabilities
NBSE's current ratio has plunged by 52% YoY but it is up by 13% from the previous quarter
NBSE's quick ratio has dropped by 51% year-on-year but it is up by 12% since the previous quarter
NBSE's debt is 42% smaller than its equity
The debt to equity has soared by 123% year-on-year and by 18% since the previous quarter
The equity has shrunk by 61% YoY and by 19% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.